179 related articles for article (PubMed ID: 18306037)
21. Protection by constitutively formed nitric oxide of intestinal damage induced by indomethacin in rats.
Tanaka A; Mizoguchi H; Kunikata T; Miyazawa T; Takeuchi K
J Physiol Paris; 2001; 95(1-6):35-41. PubMed ID: 11595416
[TBL] [Abstract][Full Text] [Related]
22. Dopamine D₂-receptor antagonists ameliorate indomethacin-induced small intestinal ulceration in mice by activating α7 nicotinic acetylcholine receptors.
Yasuda M; Kawahara R; Hashimura H; Yamanaka N; Iimori M; Amagase K; Kato S; Takeuchi K
J Pharmacol Sci; 2011; 116(3):274-82. PubMed ID: 21691039
[TBL] [Abstract][Full Text] [Related]
23. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events.
Tanaka A; Hase S; Miyazawa T; Ohno R; Takeuchi K
J Pharmacol Exp Ther; 2002 Dec; 303(3):1248-54. PubMed ID: 12438549
[TBL] [Abstract][Full Text] [Related]
24. Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats--role of anti-intestinal motility mediated by D2 receptors.
Miyazawa T; Matsumoto M; Kato S; Takeuchi K
Med Sci Monit; 2003 Feb; 9(2):BR71-7. PubMed ID: 12601282
[TBL] [Abstract][Full Text] [Related]
25. Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats.
Satoh H; Amagase K; Takeuchi K
J Pharmacol Exp Ther; 2014 Feb; 348(2):227-35. PubMed ID: 24254524
[TBL] [Abstract][Full Text] [Related]
26. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
[TBL] [Abstract][Full Text] [Related]
27. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.
Kyoi T; Noda K; Oka M; Ukai Y
Life Sci; 2004 Nov; 76(1):71-83. PubMed ID: 15501481
[TBL] [Abstract][Full Text] [Related]
28. Functional mechanism underlying cyclooxygenase-2 expression in rat small intestine following administration of indomethacin: relation to intestinal hypermotility.
Tanaka A; Matsumoto M; Hayashi Y; Takeuchi K
J Gastroenterol Hepatol; 2005 Jan; 20(1):38-45. PubMed ID: 15610444
[TBL] [Abstract][Full Text] [Related]
29. Activation of α7 nicotinic acetylcholine receptors ameliorates indomethacin-induced small intestinal ulceration in mice.
Kawahara R; Yasuda M; Hashimura H; Amagase K; Kato S; Takeuchi K
Eur J Pharmacol; 2011 Jan; 650(1):411-7. PubMed ID: 20969854
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
Kyoi T; Oka M; Noda K; Ukai Y
Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
[TBL] [Abstract][Full Text] [Related]
31. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage.
Takeuchi K; Tanaka A; Kato S; Amagase K; Satoh H
Clin Chim Acta; 2010 Apr; 411(7-8):459-66. PubMed ID: 20074562
[TBL] [Abstract][Full Text] [Related]
32. Nitric oxide inhibitors ameliorate indomethacin-induced enteropathy in rats.
Parasher G; Frenklakh L; Goodman ; Siddiqui T; Nandi J; Levine RA
Dig Dis Sci; 2001 Nov; 46(11):2536-41. PubMed ID: 11713966
[TBL] [Abstract][Full Text] [Related]
33. Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats.
Mizoguchi H; Hase S; Tanaka A; Takeuchi K
Aliment Pharmacol Ther; 2001 Feb; 15(2):257-67. PubMed ID: 11148446
[TBL] [Abstract][Full Text] [Related]
34. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats.
Konaka A; Nishijima M; Tanaka A; Kunikata T; Kato S; Takeuchi K
J Physiol Pharmacol; 1999 Mar; 50(1):25-38. PubMed ID: 10210152
[TBL] [Abstract][Full Text] [Related]
35. Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility.
Satoh H; Amagase K; Takeuchi K
J Pharmacol Exp Ther; 2012 Nov; 343(2):270-7. PubMed ID: 22854201
[TBL] [Abstract][Full Text] [Related]
36. TNF-alpha modulates iNOS expression in an experimental rat model of indomethacin-induced jejunoileitis.
Nandi J; Saud B; Zinkievich JM; Yang ZJ; Levine RA
Mol Cell Biochem; 2010 Mar; 336(1-2):17-24. PubMed ID: 19802525
[TBL] [Abstract][Full Text] [Related]
37. Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats.
Satoh H; Shiotani S; Otsuka N; Hatao K; Nishimura S
Gut; 2009 Dec; 58(12):1590-6. PubMed ID: 19060018
[TBL] [Abstract][Full Text] [Related]
38. Co-administration of Magnesium Ion Prevents Indomethacin-Induced Intestinal Ulcerogenic Lesions in Adjuvant-Induced Arthritis Rats.
Nagai N; Ueno A; Tanino T; Oka M; Ito Y
Biol Pharm Bull; 2017; 40(6):910-915. PubMed ID: 28566633
[TBL] [Abstract][Full Text] [Related]
39. Permissive role of neutrophils in pathogenesis of indomethacin-induced gastric lesions in rats.
Suzuki K; Araki H; Komoike Y; Takeuchi K
Med Sci Monit; 2000; 6(5):908-14. PubMed ID: 11208431
[TBL] [Abstract][Full Text] [Related]
40. Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis.
Yao J; Zhu Y; Sun W; Sawada N; Hiramatsu N; Takeda M; Kitamura M
Br J Pharmacol; 2007 Jun; 151(4):457-66. PubMed ID: 17435794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
